Meeting Protocols Sample Clauses

Meeting Protocols. For regular weekly project status meetings, Contractor’s Project Manager shall provide a meeting agenda and any handouts at least one business day in advance of the scheduled meeting.
AutoNDA by SimpleDocs
Meeting Protocols. For regular weekly project status meetings, Contractor’s Project Manager shall provide a meeting agenda at least one (1) business day in advance of the meeting and any handouts at least one (1) business day in advance of the scheduled meeting.
Meeting Protocols. LDM Agreement Meetings LDM Agreement Meetings will be held at least quarterly, as agreed by the NT Government and JCAC to monitor the progress of Agreement objectives and shared performance areas, with an agenda that will include but not be limited to: • recording / reporting on agreed action items • reporting on the progress of Agreement objectives and Implementation Plans • discussion of any agreement-level matters that arise from time to time • a review of the relationship between the parties • major issues / areas for improvement The meetings will be co-chaired between the JCAC Chairperson and the Regional Executive Director – Barkly Region, Department of the Chief Minister Both JCAC and the NT Government co-chairs will invite a minimum of two additional representatives (a total of 3 representatives from each party) to attend meetings A senior Commonwealth officer responsible for Indigenous Affairs in the region will also be invited to attend meetings. Local Decision Making Agreement Meetings will work towards consensus decisions. An interpreter will be made available should they be required Minutes will be taken at all meetings in English and circulated to all participants and apologies. Action items from the meeting will form part of agenda items for next meeting, and the next meeting will receive updates on whether action items were completed and, if not, what further action is required. Any changes required for Implementation Plans are agreed and minuted, and necessary changes are made and communicated to Implementation Plan representatives, and to any publicly available information. Implementation Plan Meetings The parties will hold Implementation Plan Meetings for each Schedule 2, Schedule 3 and Schedule 4 priority as often as is required to adequately develop and implement the Implementation Plans under this agreement, with an agenda that includes but is not limited to: • recording / reporting on agreed action items • Review of Implementation Plan items and progress • Review of the relationship between the parties • Review of risks and associated mitigation measures and their effectiveness • Major issues / areas for improvement JCAC and the NT Government will nominate a lead representative for each Implementation Plan. The NT Government representative will be responsible for organising Implementation Plan Meetings, inviting JCAC representative, other responsible NT Government Agencies and other agreed stakeholders. Meetings will be conducted in ...
Meeting Protocols. (a) The NBMG will be convened and meet as necessary:
Meeting Protocols. All governance meetings should follow standard business practices for meeting etiquette, as follows: o Meeting changes should be communicated at least 5 Business Days in advance. o Agendas will be jointly established and circulated together with any other meeting materials 3 Business Days prior to the meeting. o Quorum for all meetings require at least one representative of each party to be present in person or through acceptable remote access. o All decisions will be made in accordance with section 1.7 (Authority and Decision making) below. o Meeting minutes shall be taken and circulated to committee members within 3 Business Days of the meeting. o parties have three Business Days after circulation of the minutes to object to minutes, failing which minutes are deemed to be accepted. Such deeming provision shall not apply to minutes of meetings of Joint Relationship Sponsors which must be accepted by the members thereof. o Meeting invitees to indicate ability to attend at least 3 Business Days prior to the meeting and, if unable to attend, to send an appropriate delegate with decision-making authority.
Meeting Protocols i. The Architect shall attend meetings as required by the County, to include, but is not limited to: i. Schematic Design (SD) ii. Design Development (DD) iii. Construction Documents (CD)
Meeting Protocols. The board uses established meeting protocols to ensure everyone understands what will occur at board meetings. This includes a template for the board agenda, reporting templates (administration, business services, etc.), and board policy explaining how parents can bring an issue to the board and address the board if they have concerns. Board members are bound by executive session law to maintain confidentiality. In general, it is wise for board members to use discretion when at school functions and speaking outside the board room. Even though the board member may perceive him/ herself as not wearing his/her board hat, others may perceive the board member in that role. One of the board’s strengths is its wide diversity of strengths, skills, and opinions. It is these different viewpoints that allow the board to reach the best conclusions, through vigorous debate and discussions. Board members must be mindful of speaking with one voice on matters that have been voted by the full board. The board has outlined communication pathways in its policies and encourages the Executive Director to likewise clearly articulate communication pathways for staff, students, and parents. The board will adhere to these communication pathways and not circumvent the established process. Board members are expected to attend all board meetings. A member may receive an excused absence by notifying the board President or at least two other board members prior to the scheduled meeting. Board members should be aware of their fiduciary responsibility as a board member and not abstain from voting on a matter unless there is a conflict of interest that has been declared. The board will use Xxxxxx’s Rules of Order to conduct its meetings.
AutoNDA by SimpleDocs
Meeting Protocols. 8.2.1. The Architect shall attend meetings as required by the County, however limited to a number of meetings by phase as defined herein: 8.2.1.1. Schematic Design (SD) twice-monthly meetings; 8.2.1.2. Design Development (DD) twice monthly meetings; 8.2.1.3. Construction Documents (CD) 5 meetings; 8.2.1.4. Construction Administration (CA) twice monthly meetings; 8.2.2. The Architect shall not have any direct or indirect contract relationship with any officer, or employee, of the County that will conflict with his ability to perform the Services hereunder. All personnel assigned to the Services shall be fully qualified and all facilities employed shall be adequate for the Services required. 8.2.3. Attend all meetings and conferences as arranged and required by the County during the progress of the Services hereunder to establish design concepts, to review preliminary and final reports, secure agreement upon comprehensive and detailed basis of design, and discuss any other matters relating to the Services. 8.2.4. Provide the County with meeting minutes to confirm and record the understandings and agreements resulting from meetings and conferences.
Meeting Protocols i. This meeting will occur at a time when the employee is not actively instructing or supervising students.

Related to Meeting Protocols

  • Protocol No action to coerce or censor or penalize any negotiation participant shall be made or implied by any other member as a result of participation in the negotiation process.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

  • Review Protocol A narrative description of how the Claims Review was conducted and what was evaluated.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Signaling protocol 4.1.3.1 SS7 Signaling is AT&T-21STATE’s preferred method for signaling. Where MF signaling is currently used, the Parties agree to use their best efforts to convert to SS7. If SS7 services are provided by AT&T-21STATE, they will be provided in accordance with the provisions of the applicable access tariffs. 4.1.3.2 Where MF signaling is currently used, the Parties agree to interconnect their networks using MF or dual tone MF (DTMF) signaling, subject to availability at the End Office Switch or Tandem Switch at which Interconnection occurs. The Parties acknowledge that the use of MF signaling may not be optimal. AT&T-21STATE will not be responsible for correcting any undesirable characteristics, service problems or performance problems that are associated with MF/SS7 inter-working or the signaling protocol required for Interconnection with CLEC employing MF signaling.

  • Commercialization Plan At such times as the JGC will deem appropriate, the JGC will direct the Parties to mutually prepare a Worldwide Commercialization Plan, and the JGC will review and approve such initial Worldwide Commercialization Plan. Thereafter, the JGC will have one or the other Party (or both) update the Worldwide Commercialization Plan each calendar year, and the JGC will review and approve any such update or any other amendment to the Worldwide Commercialization Plan. Notwithstanding anything in this CCPS Agreement to the contrary, the Parties acknowledge and agree that (i) Bluebird may decline to perform any Commercialization activity proposed to be conducted by Bluebird in the Worldwide Commercialization Plan (other than Manufacturing of Vectors and associated Payloads), and (ii) the Worldwide Commercialization Plan will not include, and Bluebird will have no obligation to perform, any such Commercialization activity that Bluebird has declined to perform, provided that once Bluebird has agreed to perform a Commercialization activity, it will be obligated to perform, and cannot decline to perform, such activity. In addition, either Party may request at any time that the JGC consider and approve other updates to the Worldwide Commercialization Plan. Further: (a) The JGC will set the required form and contents of the Worldwide Commercialization Plan. The Worldwide Commercialization Plan will reflect a singular marketing and sales approach worldwide, and will specify, among other things, the number of sales reps in the U.S. for each Party, allocation of regions in the U.S. for each Parties’ sales force, creation of marketing materials, planning for conferences, and other marketing activities. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. (b) Neither Party (itself or by or through any others, including any Affiliates or Sublicensees) will take any material action regarding the Commercialization of Licensed Product unless described in the Worldwide Commercialization Plan or approved by the JGC. (c) All Commercialization of Licensed Product for U.S. Administration will be conducted under the supervision of the JGC and as part of the U.S. Development & Commercialization Program. (d) Celgene will have final decision making authority for all Commercialization activities worldwide, including timing of launch and pricing and the Worldwide Development Plan.

  • Marketing Plan The MCOP shall submit an annual marketing plan to ODM including all planned activities for promoting membership in or increasing awareness of the MCOP. The marketing plan submission shall include an attestation by the MCOP that the plan is accurate and is not intended to mislead, confuse, or defraud the eligible individuals or ODM.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Joint Commercialization Committee (i) The JCC shall oversee Commercialization of JAK Licensed Products in the Field worldwide. As soon as practicable following the Effective Date (but in no event more than thirty (30) days following the Effective Date), each Party shall designate its initial three (3) representatives on the JCC. The JCC shall be composed of appropriate and key executives of Novartis together with an equal number of appropriate and key executives from Incyte. Novartis and Incyte shall each appoint a person from among its representatives on the JCC to serve as the co-chairperson of the JCC. The co-chairpersons shall not have any greater authority than any other representative on the JCC and shall conduct the following activities of the JCC: (A) calling meetings of the JCC; (B) preparing and issuing minutes of each such meeting within thirty (30) days thereafter; (C) preparing and circulating an agenda for the upcoming meeting; and (D) ensuring that any decision-making delegated to the JCC is carried out in accordance with Section 3.5. (ii) The JCC shall be responsible for: (A) overseeing, reviewing and coordinating the Commercialization of JAK Licensed Products in the Field worldwide; (B) developing and overseeing the Global Branding Strategy; (C) setting overall strategic objectives and plans related to Commercialization of JAK Licensed Products in the Field worldwide; (D) reviewing, commenting on and approving the Promotional Plan; (E) reviewing Commercialization issues for JAK Licensed Products in the Field in the Novartis Territory that will have an impact on Commercialization of JAK Licensed Products in the Field in the Incyte Territory; (F) reviewing Commercialization issues for JAK Licensed Products in the Field in the Incyte Territory that will have an impact on Commercialization of JAK Licensed Products in the Field in the Novartis Territory; (G) providing a forum for the Parties to discuss the Commercialization of JAK Licensed Products in the Field worldwide; and (H) such other responsibilities as may be assigned to the JCC pursuant to this Agreement or as may be mutually agreed upon by the Parties from time to time.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!